Inovotion

Inovotion operates as a preclinical contract research organization (CRO) specializing in oncology and cell therapy. Its core technology is a rapid, sensitive, and cost-effective in vivo xenograft assay using the chicken embryo CAM model, validated with over 55 human tumor cell lines and 30 reference drugs. The company serves pharmaceutical and biotech clients by offering services for target validation, efficacy and toxicity testing, and multi-cancer screening, positioning itself as an alternative to traditional murine models that aligns with the 3Rs principles (Replacement, Reduction, Refinement).

Proprietary chicken egg chorioallantoic membrane (CAM) xenograft assay for in vivo tumor growth, metastasis, and drug response testing. Validated with >55 human tumor cell lines and >30 reference drugs.

Inovotion competes in the preclinical CRO market, specifically against providers of murine xenograft services and other alternative model platforms (e.g., zebrafish, organoid-based assays). Its differentiation lies in the specific combination of an in vivo, vascularized environment with the speed, cost, and ethical advantages of the chicken embryo model.